Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ADAM9 deficiency mediates KRAS related pathways in pancreatic cancer cells

ABSTRACT: ADAM9 deficiency mediates KRAS related pathways in pancreatic cancer cells

PROVIDER: PRJNA1028989 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26410356_1.fastq.gz	Fastqsanger.gz
	SRR26410356_2.fastq.gz	Fastqsanger.gz
	SRR26410357_1.fastq.gz	Fastqsanger.gz
	SRR26410357_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

ADAM9 deficiency mediates KRAS related pathways in pancreatic cancer cells

Project description:Kirsten rat sarcoma virus (KRAS) signaling drives pancreatic ductal adenocarcinoma (PDAC) malignancy, which is an unmet clinical need. Here we identify a disintegrin and metalloproteinase domain 9 (ADAM9) as a modulator of PDAC progression via stabilization of wild-type and mutant KRAS proteins. Mechanistically, ADAM9 loss increases the interaction of KRAS with plasminogen activator inhibitor-1 (PAI-1), which functions as a selective autophagy receptor in conjunction with LC3, triggering the lysosomal degradation of KRAS. Suppression of ADAM9 by a small molecule inhibitor restricts disease progression in spontaneous models, and the combination with gemcitabine elicits dramatic regression of patient-derived tumors. Our findings provide a promising strategy to target the KRAS signaling cascade and demonstrate a potential modality to enhance sensitivity to chemotherapy in PDAC.

2023-12-11 | GSE245560 | GEO

Inhibition of ADAM9 mediates KRAS-related pathways in pancreatic cancer cells

2023-12-11 | GSE245819 | GEO

Inhibition of ADAM9 mediates KRAS-related pathways in pancreatic cancer cells

Project description:Inhibition of ADAM9 mediates KRAS-related pathways in pancreatic cancer cells

| PRJNA1030022 | ENA

ARID1A deficiency promotes pancreatic tumorigenesis by reducing KRAS-induced senescence

Project description:ARID1A deficiency promotes pancreatic tumorigenesis by reducing KRAS-induced senescence

| PRJNA673200 | ENA

ARID1A deficiency promotes pancreatic tumorigenesis by reducing KRAS-induced senescence (ATAC-Seq)

Project description:ARID1A is one of the most frequently mutated epigenetic regulators in a wide spectrum of cancers. In this study, we identified the anti-senescence effect of ARID1A deficiency in the progression of pancreatic intraepithelial neoplasia (PanIN) by profiling the transcriptome of individual PanINs in the mouse model. Interestingly, we found that ARID1A deficiency activates the transcription of Aldehyde dehydrogenase 1 family, member A1 (ALDH1A1), which play essential roles in attenuating the senescence by significantly reducing reactive oxygen species (ROS) induced by oncogenic KRAS. Our findings further suggest that ALDH could be considered as a potential adjuvant target for prevention and treatment of pancreatic cancer.

2021-06-06 | GSE160440 | GEO

ARID1A deficiency promotes pancreatic tumorigenesis by reducing KRAS-induced senescence (RNA-Seq I)

2021-06-06 | GSE160442 | GEO

ARID1A deficiency promotes pancreatic tumorigenesis by reducing KRAS-induced senescence (RNA-Seq II)

2021-06-06 | GSE160443 | GEO

RBPJ deficiency sensitizes pancreatic acinar cells to Kras-mediated PanIN initiation

Project description:RBPJ deficiency sensitizes pancreatic acinar cells to Kras-mediated PanIN initiation

| PRJNA784421 | ENA

E2F1 mediates SOX17 Deficiency-Induced Pulmonary Hypertension

Project description:E2F1 mediates SOX17 Deficiency-Induced Pulmonary Hypertension

| PRJNA792563 | ENA

ARID1A deficiency promotes pancreatic tumorigenesis by reducing KRAS-induced senescence (ATAC-Seq)